Enzolytics
Candidate: Anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 Types: Fully human monoclonal antibodies targeting immutable sites confirmed as 98.71% to 99.29% conserved over the entirety of all 1 million coronavirus isolates. Enzolytics says it has confirmed that the analyzed sites are conserved sites not only on the initial virus strains but also existing in the Delta and Lambda variants, as well […]
Read more